BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE™ Disease Management Platform

Chronic disease rates in the U.S. are on the rise in spite of the number of effective therapies available. In fact, chronic diseases are the leading causes of death and disability and the leading drivers of the country’s $3.8 trillion annual health care costs.

Digital technology has the potential to play an impactful role in chronic disease management by improving patient engagement and therapy adherence, as well as empowering healthcare providers with better insights to deliver more personalized care in real-time.

Our client, AstraZeneca, engaged BrightInsight to build a platform that would allow AstraZeneca to partner with healthcare systems to improve the care of patients suffering from chronic disease(s). The vision required a cloud-based platform with pre-built functionality – including clinical workflow integration – to speed time to market for AstraZeneca’s Disease Management Platform in a way that supports privacy, security and regulatory requirements.

From Project Kick-off to Commercialization in Less Than 12 Months

I’m pleased to share that today BrightInsight announced the launch of the AstraZeneca AMAZETM Disease Management Platform, which aims to improve patient outcomes by providing an end-to-end digital solution closing the gap between patient and providers across multiple chronic conditions including COPD, asthma, chronic kidney disease and heart failure.

Comprised of a patient mobile application that integrates with digital devices (IoT) and a clinician dashboard integrated into the Electronic Health Record (EHR), the AstraZeneca AMAZE Platform captures pertinent clinical information through connected devices, supports quality of life measures and Patient-Reported Outcomes (PROs), and provides a direct communication channel between the patient and their care team.

From project kick-off to go-live in less than 12 months, BrightInsight’s proven platform and pre-built functionality significantly accelerated AstraZeneca’s time to market.

COVID-19’s Impact on Chronic Disease Management

COVID-19 has exposed the need for digital solutions and shown us that remote care is not only preferred but necessary. And it’s being adopted at a high rate. 47% of patients say their communication with providers was more personalized using digital than traditional in-office visits. There’s no going back now, and companies like AstraZeneca are leading the industry with transformational digital health initiatives like the AMAZE Disease Management Platform.

You can learn more about the AMAZE Disease Management Platform and our collaboration in our latest Case Study here.

Back to Blog